GlassScriptPhysician profile
Karen Beasley
NPI 1013990258
$3,509.46
in general payments reported to CMS, 2019-2025
28 companies · $609 in 2025
The $609 reported for 2025 was more than what 82% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $567 · 2020: $117 · 2021: $203 · 2022: $610 · 2023: $457 · 2024: $946 · 2025: $609.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,818 · Education: $195.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,817.72 |
| Education | $194.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $600.02 | 2020-2025 | Tremfya, Simponi Aria, Simponi |
| Abbvie INC. | $476.10 | 2019-2025 | Botox |
| E.R. Squibb & Sons, L.L.C. | $444.36 | 2022-2025 | Sotyktu |
| Galderma Laboratories, L.P. | $266.26 | 2019-2025 | Aklief, Nemluvio, Epsolay |
| Regeneron Healthcare Solutions, INC. | $186.80 | 2019-2025 | Dupixent, Libtayo |
| Pfizer INC. | $167.76 | 2019-2025 | |
| Arcutis Biotherapeutics, INC. | $123.38 | 2023-2025 | Zoryve |
| Allergan, INC. | $119.26 | 2019-2022 | |
| Revance Therapeutics, INC. | $116.68 | 2024 | Daxxify |
| Genzyme Corporation | $101.61 | 2019-2025 | |
| Incyte Corporation | $100.04 | 2022-2024 | Opzelura |
| Lilly USA, LLC | $85.46 | 2022-2025 | Taltz, Ebglyss, Olumiant |
| Dermavant Sciences, INC. | $84.64 | 2023 | Vtama |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $74.40 | 2024-2025 | Cabtreo, Siliq, Jublia |
| Aclaris Therapeutics, INC. | $67.39 | 2019 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $63.41 | 2022-2024 | Otezla |
| Biofrontera INC. | $57.96 | 2019-2021 | |
| Elekta, INC. | $53.11 | 2024 | Elekta Medical Linear Accelerator |
| Ucb, INC. | $51.66 | 2021-2025 | Bimzelx |
| Almirall LLC | $45.45 | 2019-2021 | |
| Epi Health, LLC | $42.39 | 2022 | |
| Sun Pharmaceutical Industries INC. | $33.86 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $33.20 | 2022 | |
| Novartis Pharmaceuticals Corporation | $29.80 | 2025 | |
| Botanix Sb INC | $25.21 | 2025 | Sofdra |
| Dermira, INC. | $24.25 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $18.78 | 2019 | |
| Merz North America, INC. | $16.22 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Karen Beasley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.